Citi upgraded Haemonetics (HAE) to Buy from Neutral with a price target of $90, up from $71. The firm believes the company’s path forward is “more derisked” following the fiscal 2026 guidance update. Haemonetics’ plasma share gains are not factored into contracts, which will support high-single-digit core revenue growth and high-teens earnings growth, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE: